In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia. Orna Therapeutics (through its wholly owned ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

CRISPR Therapeutics and Vertex Pharmaceuticals are also conducting separate late-stage studies to expand Casgevy’s label in pediatric patients with SCD and TDT.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

Vertex has already mentioned that it is experiencing a strong launch for Casgevy. We expect the company to start recording collaboration revenues from the therapy’s sales in the fourth quarter of 2024 ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...

Collectively, these elements underscore Arcturus Therapeutics’ capacity for innovation and market penetration, justifying the Buy rating. ARCT’s price has also changed moderately for the past ...

CRISPR Therapeutics (NASDAQ:CRSP) could be an attractive takeover ... What’s more, some analysts suggest there is a ready-made buyer in CRISPR’s partner on Casgevy, Vertex Pharmaceuticals. Now Vertex ...